¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Chronic obstructive lung disease"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • minimal change disease
    ¹Ì¼¼º¯È­º´
  • malabsorption disease
    Èí¼öÀå¾Öº´
  • mixed connective tissue disease
    È¥ÇÕ°áÇÕÁ¶Á÷º´
  • molecular disease
    ºÐÀÚº´
  • Monge disease
    ¸ùÇ캴
  • motor neuron disease
    ¿îµ¿½Å°æ¼¼Æ÷º´, ¿îµ¿½Å°æ¿øº´
  • mountain disease
    °í»êº´
  • moyamoya disease
    ¸ð¾ß¸ð¾ßº´
  • muscle disease
    ±ÙÀ°º´
  • mycobacterial disease
    Ç×»ê±Õº´, ¹ÌÄÚ¹ÚÅ׸®¾Æº´
  • mycoplasma disease
    ¹ÌÄÚÇö󽺸¶º´
  • maple syrup urine disease
    ´Üdz½Ã·´´¢º´
  • marble bone disease
    ´ë¸®¼®º´, °ñÈ­¼®º´
  • Marburg disease
    ¸¶¸£ºÎ¸£Å©º´
  • Marburg virus disease
    ¸¶¸£ºÎ¸£Å©¹ÙÀÌ·¯½ºº´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • occlusive cerebrovascular disease
    Æó¼â³úÇ÷°üÁúȯ
  • occupational disease
    Á÷¾÷º´
  • occupational dental disease
    Á÷¾÷Ä¡°úº´
  • oculoglandular disease
    ´«»ùº´
  • oral disease
    ÀÔº´, ±¸°­Áúȯ
  • organic disease
    ±âÁúº´
  • pandemic disease
    ¹üÀ¯Çິ
  • panzootic disease
    µ¿¹°¹üÀ¯Çິ
  • parasitic disease
    ±â»ýÃæº´
  • paroxysmal disease
    ¹ßÀÛº´
  • pelvic inflammatory disease
    °ñ¹Ý³»°¨¿°
  • periapical disease
    Ä¡±Ù´ÜÁÖÀ§º´, Ä¡¾Æ³¡ÁÖÀ§º´
  • pericardial disease
    ½ÉÀ帷º´
  • periodontal disease
    Ä¡ÁÖº´, Ä¡±Ù¸·º´
  • peripheral vascular disease
    ¸»ÃÊÇ÷°üº´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • glucuronidase deficiency disease
    ±Û·çÅ¥·Î´Ïµ¥À̽º °áÇÌÁõ
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀû Áúȯ.
  • glycogen storage disease
    ´ç¿ø ÃàÀûÁúȯ(ÓØê«õëîÝòðü´)
  • glycogen storage disease
    ±Û¸®ÄÚ°ÕÃàÀûÁúȯ
  • graft versus host disease
    ´ë¼÷ÁÖÀÌ½ÄÆíÁúȯ
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´.
  • graft versus host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë¼÷ÁÖº´
  • graft-versus-host disease
    ÀÌ½ÄÆí´ë ¼÷ÁÖº´
  • granulomatous disease
    À°¾ÆÁ¾¼º Áúȯ.
  • granulomatous disease
    À°¾ÆÁ¾¼º Áúȯ
  • granulomatous disease of childhood
    ¼Ò¾ÆÀ°¾ÆÁ¾¼º Áúȯ.
  • granulomatous disease of childhood
    ¼Ò¾Æ À°¾ÆÁ¾¼º Áúȯ
  • graves disease
    ±×·¹À̺꽺 º´, Grave º´
  • grinder s disease ; silicosis
    ±ÔÆóÁõ, ºÐ¼â±â°øº´.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • lung cancer
    Æó¾Ï
  • lung cancer
    Æó¾Ï(Æó¾Ï).
  • lung cancer
    Æó¾Ï(øË ).
  • lung capacity
    Æó¿ë·®(øËé»åÖ).
  • lung circulation
    Æó¼øÈ¯(øËâàü»).
  • lung collapse
    ÆóÇãÅ»(øËúÈ÷­).
  • lung compliance
    Æóź¼º,ÆóÀ¯¼øµµ
  • lung compliance
    Æóź¼º(øË÷¥àõ).
  • lung correction factor
    Æóº¸Á¤°è¼ö
  • lung deflation reflex
    Æó¼öÃà¹Ý»ç(øËâ¥õêÚãÞÒ).
  • lung fever
    Æó¿­(øËæð).
  • lung field
    ¹æ»ç °áÇÙÆó¾ß(øËå¯).
  • lung fluke
    ÆóÈíÃæ(øËýåõù).
  • lung fluke infection
    ÆóÈíÃæ°¨¿°(¡­Êïæø).
  • lung infarction
    Æó°æ»öÁõ(øËÌãßáñø).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
CNDC chronic nonspecific diarrhea of childhood; chronic nonsuppurative destructive cholangitis
CPN central parenteral nutrition; chronic polyneuropathy; chronic pyelonephritis
CRF case report form; chronic renal failure; chronic respiratory failure; coagulase-reacting factor; con...
CRI Cardiac Risk Index; catheter-related infection; chronic renal insufficiency; chronic respiratory ins...
ACD   1) Absolute Cardiac Dullness; Àý´ë½ÉµÐŹÀ½
  2) Anemia of Chronic Disease
&nbs...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
TLW Total lung water
TBLB Transbroncheal lung biopsy
TBB Transbronchial lung biopsy
TRALI Transfusion-related acute lung injury
EEV end expiratory lung volume
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • legal communicable disease
    ¹ýÁ¤ Àü¿°º´
    Àü¿°º´ ¿¹¹æ¹ý Á¦2Á¶ 1Ç׿¡¼­ ¿­°Å ±ÔÁ¤Çϰí ÀÖ´Â Àü¿°º´. Á¦1Á¾, Á¦2Á¾ ¹× Á¦3Á¾À¸·Î ³ª´©¾îÁø´Ù. 93³â 12¿ù ¼öÁ¤, °áÁ¤µÈ ¹ýÁ¤ Àü¿°º´Àº ¸ðµÎ 28Á¾ÀÌ´Ù. Áï, Á¦1Á¾Àº ÄÝ·¹¶ó, Æä½ºÆ®, ¹ßÁøÆ¼Çª½º, ÀåÆ¼Çª½º, ÆÄ¶óƼǪ½º, µðÇÁÅ׸®¾Æ, ¼¼±Õ¼º ÀÌÁú, Ȳ¿­, Á¦2Á¾Àº Æú¸®¿À, ¹éÀÏÇØ, È«¿ª, À¯Ç༺ ÀÌÇϼ±¿°, ÀϺ» ³ú¿°, °ø¼öº´, ¸»¶ó¸®¾Æ, ¹ßÁø¿­, ¼ºÈ«¿­, Àç±Í¿­, ¾Æ¸Þ¹Ù¼º ÀÌÁú, ¼ö¸· ±¸±Õ¼º ¼ö¸·¿°, À¯Ç༺ ÃâÇ÷¿­, ÆÄ»ódz, ÈÄõ¼º ¸é¿ª °áÇÌÁõ, ·¾Å佺ÇǶóÁõ, ¾²¾²°¡¹«½Ã º´, Á¦3Á¾Àº °áÇÙ, ¼ºº´, ³ªº´À¸·Î µÇ¾î ÀÖ´Ù. Àü¿°º´ ¿¹¹æ¹ýÀº ¹ýÁ¤ Àü¿°º´¿¡ ´ëÇÑ ÀÇ»ç, È£ÁÖ, ¼¼´ëÁÖ, ±âŸ °¢ ±â°üÀÇ ±â°üÀåÀ̳ª °æ¿µÀÚ, ±º ºÎ´ëÀå µîÀÇ ½Å°í ¹× º¸°í Àǹ«¿Í °Ç°­ Áø´Ü, ¿¹¹æ Á¢Á¾, °Ý¸®, ÀÔ¿ø Á¶Ä¡, °¢Á¾ ¿¹¹æ Á¶Ä¡ µîÀ» ±ÔÁ¤Çϰí ÀÖ´Ù.
  • Legg-Calve-Perthes disease
    ·¹±×-Ä®º£-ÆÆä¸£Å×½
  • Legionnaires'disease
    ÀçÇⱺÀÎ º´
    Legionella °¨¿°Àº »çȸ ȹµæ Æó·ÅÀÇ 3-4¹øÂ°·Î ÈçÇÑ ¿øÀÎÀÌ´Ù. ¿øÀÎÀ» Àß ¸ð¸£´Â Æó·ÅÀÇ °æ¿ì´Â ¾ðÁ¦µçÁö °í·ÁÇØ¾ß ÇÑ´Ù. ÀçÇⱺÀÎ º´Àº ¸é¿ª ÀúÇÏÀÚ¿Í Èí¿¬ÀÚ, ¸¸¼º Æó ÁúȯÀÚ¿¡¼­ Á»´õ ÈçÇÏ´Ù. ·¹Áö¿À³Ú¶óÁõÀÇ Áý´Ü ¹ß»ýÀº »þ¿ö±â³ª ¼öµµ²ÀÁö¿Í ¿¡¾îÄÁÀÇ ³Ã°¢ ž°ú °°Àº ¿À¿°µÈ ¼ö¿ø°ú ¿¬°üµÇ¾î ÀÖ´Ù. ÀÌ º´Àº °´´ãÀÇ ±×¶÷ ¿°»ö¿¡¼­ ±ÕÀÌ º¸ÀÌÁö ¾Ê±â ¶§¹®¿¡ ÈçÈ÷ ºñÁ¤Çü Æó·ÅÀ̶ó°í ÇÑ´Ù. ±×·¯³ª ÀÌ º´ÀÇ ÀÓ»ó Áõ»óÀº °í¿­°ú Áßµ¶¼º ¿Ü°ß, ´Á¸·¿°, È­³ó¼º °´´ã
  • Letter Siwe disease
    ·¹ÅÍ·¯ ½Ã¿þ º´
    ¾Ç¼º Á¶Á÷±¸ÁõÀ̳ª ¾Ç¼º ÀÓÆÄÁ¾°ú °°Àº ¾çÅÂÀÌ´Ù. 2¼¼ ÀÌÇÏÀÇ À¯¾Æ¿¡ ¹ßº´ÇÏ°í ´ë°³ Ä¡¸íÀûÀÌ´Ù. ±âº»ÀûÀÎ º´¸® ¼Ò°ßÀº ÀÓÆÄÀý, ÇǺÎ, Æó, °ñ¼öÀÇ º´¹ßÀ̳ª °£ ºñ´ë¸¦ ÃÊ·¡ÇÏ´Â ¼¼¸Á³»Çǰè ÁúȯÀ¸·Î º´º¯ÀÇ ÁøÇà ¼Óµµ°¡ ºü¸£±â ¶§¹®¿¡ ¹æ»ç¼±ÇÐÀû °Ë»ç°¡ ºÒ°¡´ÉÇÏ´Ù.
  • linear IgA disease
    ¼±»ó ¸é¿ª ±Û·ÎºÒ¸° A Áúȯ
  • liver disease
    °£ Áúȯ
  • lymphoproliferative disease
    ÀÓÆÄ ¼¼Æ÷ Áõ½Ä¼º Áúȯ
  • Majocci's disease
    ¸¶¿äŰ º´
    Àڹݺ´.
  • Malassez's disease
    ¸»¶ó¼¼ º´
    °íȯÀÇ ³¶Æ÷.
  • manager disease
    ¸Å´ÏÀú º´
    ¿©·¯ °¡Áö º¹ÀâÇÑ ¾÷¹«¿¡ ¹Ù»Ú°Ô ½Ã´Þ¸®´Â °ü¸® Á÷±ÞÀÇ »ç¶÷¿¡°Ô¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Â º´. Çù½ÉÁõ, ƯÈ÷ °ü»ó µ¿¸Æ Ç÷ÀüÁõ µîÀÇ ½ÉÀå Ç÷°ü°è Áõ¼¼µé¸¸À» °¡¸®Å°´Â °ÍÀ̾ú´Âµ¥ Á¡Â÷·Î È®´ëµÇ¾î ¼ÒÈ­¼º ±Ë¾ç, ´ç´¢º´, ³ëÀÌ·ÎÁ¦, Ç÷¾Ð Àå¾Ö µîµµ Æ÷ÇԵȴÙ.
  • maple syrum urine disease
    ´Üdz ³ª¹« ½Ã·´ º´
    Ãø¼â, ¾Æ¹Ì³ë»ê ´ë»çÀÇ È¿¼Ò °á¼Õ¿¡ ÀÇÇÑ À¯Àüº´À¸·Î, Ç÷Àå ¹× ¿äÁß¿¡¼­ ŰÅä»ê
  • maple syrup urine disease
    ´Üdz ´ç¹Ð ´¢ Áúȯ
    Ãø¼â ¾Æ¹Ì³ë»ê ´ë»çÀÇ È¿¼Ò °á¼Õ¿¡ ÀÇÇÑ À¯Àüº´À¸·Î, Ç÷Àå ¹× ¿äÁß¿¡¼­ ŰÅä»ê[valine, leucine, isoleucine]ÀÇ ½ÉÇÑ Áõ°¡¸¦ º¼ ¼ö ÀÖ´Ù. ÀÓ»óÀû Ư¡Àº Á¤½Å Áöü ¹ß´Þ Áö¿¬, Æ÷À¯ °ï¶õ, ¿äÃë µîÀÌ´Ù.
  • marble bone disease
    °ñ È­¼®Áõ, ´ë¸®¼® °ñº´
    ´ß ¹éÇ÷º´ À°Á¾±º¿¡ ¼ÓÇÏ´Â º´. °ñÇü ¸²ÇÁÁ¾À̶ó°íµµ ÇÏ´Â ÀÌ º´Àº, »À°¡ ±½¾îÁö´Â °ÍÀÌ Æ¯Â¡À̸ç, ¹ß»ýÀÌ µå¹°±â ¶§¹®¿¡ °æÁ¦ÀûÀ¸·Î Å« ¶æÀº ¾ø´Ù. Ç÷±¸¿Í ÀüÇô °ü°è¾øÀÌ »À ¼¼Æ÷°¡ Áõ½ÄÇϹǷΠÇ÷±¸¿¡¼­ À¯·¡ÇÏ´Â Á¾¾çÀÌ ¾Æ´Ï¶ó, ¹éÇ÷º´°ú °°Àº ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ ÀϾ´Â º´À̱⠶§¹®¿¡ ¹éÇ÷º´À¸·Î Ãë±ÞµÈ´Ù.
  • Marchiafava-Bignami disease
    ¸¶¸£Å°¾ÆÆÄ¹Ù-ºñ³Ä¹Ì º´
    ³ú·®ÀÇ ÁøÇ༺ ÅðÇà º¯¼ºÀ¸·Î¼­ ÁøÇ༺ ÁöÀû ȲÆó, Á¤¼­ Àå¾Ö, Âø¶õ, ȯ°¢, ÁøÀü, °­Á÷, °æ·ÃÀÌ Æ¯Â¡. ÁÖ·Î Á߳⠳²ÀÚ Áß ¾ËÄÝ Áßµ¶ÀÚ, ƯÈ÷ ´Ù·®ÀÇ »ýÆ÷µµÁÖ¸¦ ¸¶½Ã´Â »ç¶÷¿¡°Ô Àß °É¸®´Â µå¹® Áúº´ÀÌ´Ù.
  • Marek's disease
    ¸¶·¹Å© º´
    Æ÷Áø ¹ÙÀÌ·¯½º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
Akureyri disease An epidemic disease characterised by stiffness of the neck and back, headache, diarrhoea, fever, and localised muscular weakness; restricted almost exclusively to adults, affecting women more than men; probably viral in origin.
Synonym: Akureyri disease, benign myalgic encephalomyelitis, epidemic myalgic encephalomyelitis, Iceland disease.
(05 Mar 2000)
Albers-Schonberg disease The formation of abnormally dense bone, as opposed to osteoporosis.
(18 Nov 1997)
Albert's disease Achillobursitis involving inflammation of the bursa between the Achilles tendon and the os calcis.
Synonym: Swediauer's disease.
(05 Mar 2000)
Albright's disease <syndrome> The abnormal development of multiple bones, hormonal disorder and brownish skin lesions.
(27 Sep 1997)
alcoholic liver disease <gastroenterology> Alcoholic cirrhosis is a condition of irreversible liver disease due to the chronic inflammatory and toxic effects of ethanol on the liver.
In cirrhosis, the liver cells are replaced by fibrous scar tissue. Fibrosis leads to the development of portal hypertension. The development of cirrhosis is directly related to the duration and quantity of alcohol consumption.
The manifestations of cirrhosis are related to the liver's inability to not adequately remove waste products from the bloodstream and the effects of portal hypertension.
(15 Nov 1997)
aleutian mink disease A slow progressive disease of mink caused by the aleutian mink disease virus. It is characterised by poor reproduction, weight loss, autoimmunity, hypergammaglobulinaemia, increased susceptibility to bacterial infections, and death from renal failure. The disease occurs in all colour types, but mink which are homozygous recessive for the aleutian gene for light coat colour are particularly susceptible.
(12 Dec 1998)
aleutian mink disease virus A species of parvovirus that causes a disease in mink, mainly those homozygous for the recessive aleutian gene which determines a desirable coat colour.
(12 Dec 1998)
alexander disease <radiology> Dysmyelinating disease, rare, sporadic, usually presents in 1st year, gradual enlargement of head (Differential diagnosis: Canavan disease), retardation, convulsion, spasticity CT findings: decreased density of white matter, frontal lobe predominance, with or without dilated lateral ventricles Diagnosis: brain biopsy
(12 Dec 1998)
Alexander's disease A rare, fatal central nervous system degenerative disease of infants, characterised by psychomotor retardation, seizures, and paralysis; megaloencephaly is associated with widespread leukodystrophic changes, especially in the frontal lobes.
(05 Mar 2000)
alkali disease A term applied to various animal poisonings of plant and mineral origin in arid regions under the belief that they were caused by the ingestion of alkaline waters; e.g., botulism of wild ducks, caused by feeding on decayed vegetation in nearly dried-up lakes.
(05 Mar 2000)
Almeida's disease <microbiology> A chronic fungal infection caused by Paracoccidioides brasiliensis.
It is characterised by primary pulmonary lesions with dissemination to many visceral organs.
Common findings include ulcerative granuloma lesions to the buccal mucosa (inner lining of the cheek) and nasal mucosa that extend to the surrounding skin. Generalised lymphangitis is also typical.
More commonly seen in South America and the tropics.
(15 Nov 1997)
Alpers disease Familial progressive spastic paresis of extremities with progressive mental deterioration, with development of seizures, blindness and deafness, beginning during the first year of life, and with destruction and disorganization of nerve cells of the cerebral cortex.
Synonym: Alpers disease, Christensen-Krabbe disease, progressive cerebral poliodystrophy.
(05 Mar 2000)
alpha chain disease A vague or indefinite term; could be used for alpha-heavy-chain disease (a lymphoplasma cell proliferative disease usually seen in Mediterranean men, characterised by intestinal involvement with steatorrhoea, often progressive with fatal outcome) or a thalassaemia (a genetic abnormality in the alpha globin chain of haemoglobin).
(05 Mar 2000)
altitude disease A condition that results from prolonged exposure to high altitude.
Symptoms include a continuous dry cough, shortness of breath, poor exercise tolerance, dizziness, headache, sleep difficulty, anorexia, confusion, fatigue and a rapid pulse.
Treatment includes the immediate movement to a lower altitude. Prophylaxis has been accomplished successfully with the use of acetazolamide (Diamox).
(27 Sep 1997)
alzheimer disease A degenerative organic mental disease characterised by progressive brain deterioration and dementia. The disease was originally described as dementia, presenile occurring in persons under the age of 65 (as opposed to dementia, senile with onset at or after 65); however, onset may occur at any age. There is no pathophysiological nor clinical distinction between the two stages of onset of alzheimer's. Women appear to be affected twice as frequently as men. It is characterised pathologically by the triad of senile plaques, neurofibrillary tangles, and neuropil threads.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á